|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
OREXIGEN Therapeutics, Inc.
| | | Phone: | (858) 875-8600 | Fax: | (858) 436-8650 | Year Established: | 2002 | Employees: | 16 | Ticker: | OREX | Exchange: | NASDAQ | Main Contact: | Michael Narachi, President & CEO | | Company Description | Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development.
On April 23, 2018, Orexigen Therapeutics announced it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals to sell substantially all of the assets of the company, subject to court approval. | |
|
|
|
|
|